CMS' (Centers for Medicare & Medicaid Services) OPT (ocular photodynamic therapy) with verteporfin decision cheers QLT/Novartis
This article was originally published in Clinica
Executive Summary
The Centers for Medicare & Medicaid Services (CMS) has finally settled on a coverage policy for ocular photodynamic therapy (OPT) with verteporfin, the only known treatment of the eye condition known as age-related macular degeneration (AMD). The agency announced on January 29 that it is prepared to cover the product for patients with two forms of "wet" AMD caused by the development of abnormally leaky blood vessels known as choroidal neovascularisation (CNV).